NF-κB signaling is constitutively active in CLL (Furman et al., 2000), while high levels of the pro-survival gene BCL2, an established NF-κB target, are a hallmark of the disease (Scarfò and Ghia, 2013). The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.